The Federal Department of Health has issued Version 5 of the revised guidelines for preparing a submission to the Pharmaceutical Benefits Advisory Committee, and is requesting feedback from the public. Comments close on 5 April. Although these guidelines are primarily intended for manufacturers seeking reimbursement of drugs, health professionals and members of the public may also wish to comment.
The Foundation welcomes relevant comments from the public on the matter. Please provide by 26 March 2016 by emailing [email protected]
To read the revised PBAC guidelines, click here.
22 February 2016